Table 4.
Clinical outcome.
| CD34 sel | CD3/CD19 dep | P | |
|---|---|---|---|
| n = 11 | n = 29 | ||
| Engraftment | |||
| Neutrophils engraftment | 0.054 | ||
| Median (range) days | 17 (11–22) | 12 (10–24) | |
| Graft vs. host disease | |||
| Acute GvHD | 1 | ||
| Without | 4 | 11 | |
| Grade I/II | 2/3 | 12/2 | |
| Grade III/IV | 1/1 | 3/1 | |
| Site of aGVHD | |||
| Skin | 4 | 13 | |
| Skin, GI | 1 | 2 | |
| Skin, GI, liver | – | 1 | |
| Skin, GI, lung | 1 | 2 | |
| No data | 1 | 0 | |
| Chronic GvHD | 3 | 2 | 0.117 |
| Cause of death | |||
| Relapse | 4 | 9 | |
| Treatment-related mortality | 3 | 5 | |
GvHD, graft vs. host disease; GI, gastrointestinal. P-value was calculated using Fisher-Exact test or Mann–Whitney–Wilcoxon test.